Supply chain & logistics 50%
Vaccines are wasted globally due to a lack of temperature control, logistics and shipment issues. WHO
future. And we have a recruitment crisis – can we get enough operatives in our warehouses, and enough drivers to drive the refrigerated temperature- controlled trucks that exist in the cold chain?” He says progress is already being made in each of these spheres but believes that AI and other sophisticated technologies have the potential to accelerate that further. “When you look at these issues, it makes complete sense to look at how we can become much more efficient in the supply chain itself, and that’s where AI, new technology and predictive analytics all comes into play. I think times are very, very exciting.”
Indeed, he says data is already making a difference by making it easier to understand which temperature-controlled drugs are needed where. “Looking at our analytics, both historical and current, and taking into account seasons, the climate of the surroundings, we have enough analytics to understand what drugs need to be where and in what quantity. What that means is that we will have a hugely efficient distribution network and storage network moving forward, because we can feed in those analytics,” he suggests.
“It’s not unusual for a pharmaceutical delivery vehicle to operate today at 5°C, but then it picks up another order tomorrow, and it will then be operating at -15°C.”
Phil Pluck
And in an age of increasingly extreme temperatures, there is the potential to identify refrigeration failures before they happen. “If we’re storing drugs at, let’s say, -25°C then there will normally be an enormous warehouse roof,” says Pluck. “It’s got solar panels on it, but if the temperature outside goes to 40°C, what that means really is the temperature of that roof is really sitting at about 51°C or 52°C in the sun. In order to keep -25°C underneath that roof, what’s going to happen is your refrigeration unit is going to have to work harder and harder. “What we’re now introducing is predictive technology into large-scale refrigeration units. That means it predicts when something is likely to break down under certain circumstances and it predicts when we need to do maintenance.”
Protecting products – and patients – through smarter cold chains It is not only storage units for which this is useful; it equally applies to vehicles being used to transport drugs. Pluck says this is important for pharmaceuticals because while refrigerated food deliveries involve keeping a consistent temperature between jobs, the same is not true for drugs.
34
“It’s not unusual for a pharmaceutical delivery vehicle to operate today at 5°C, but then it picks up another order tomorrow, and it will then be operating at -15°C. And then the next day it’s operating at -30°C.
“Those variations in temperature are not unusual and what that means is it’s more stress on the refrigeration units; more stress means more breakdown, which means that actually those drugs are not getting where they need to go. So those predictive elements of AI can drive down the costs by predicting those maintenance issues and understanding precisely when that point of failure is likely to happen. And for critical temperature-control drugs, that is a bit of a game-changer in terms of how we distribute those drugs.” Certainly, there is a growing number of products for which such insight is likely to be useful. The growth in biologics, derived from living organisms, brings with it more drugs that require temperature control. And vaccines provide a continuous demand for an effective cold chain. Notably, it is a demand that is frequently not met. In the past, the World Health Organisation has estimated that up to ~50% of vaccines are wasted globally, largely due to lack of temperature control, logistics and shipment issues.
Such failures have a human price but also affect the financial bottom line for companies. That is particularly the case as drugs become more complex and thus more expensive to develop.
“Over the past 25 years, the cost of these products – to develop them, and then the products themselves – is such that they have become invaluable,” argues Bacon.
“The costs are so tremendous that you can be shipping millions of dollars in a small box. And many of these products are life-saving drugs. If they don’t get to where they need to be at the right temperature and the right time, it could be a very negative outcome for the patient.”
It is a point he says he always emphasises to colleagues within pharmaceutical cold chains. Indeed, asked what companies need to do if they are to capitalise on the latest technological developments, he says they need to build an understanding of this theme. “You need very tight and compliant procedures in a cold chain, and then what follows is training [to help people understand why temperature regulation and compliance is so important]. This is where a lot of companies fail, because they take things for granted. The companies that do best are the companies that keep those things top of mind.” Ultimately, he says that companies reviewing investment in temperature-control technologies need to consider the stakes. “It’s not just a package,” he stresses. “It’s a patient.” ●
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85
